EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted therapy in the treatment of lung cancer in Iceland 2010–2023

Stefanía Ásta Tryggvadóttir, Guðlaugur V Stefánsson, Helgi Birgisson, Örvar Gunnarsson, Tómas Guðbjartsson, Hrönn Harðardóttir, Bylgja Hilmarsdóttir iD, Rósa B Barkardóttir, Sigurdis Haraldsdottir iD

Acta Oncologica · 2026

DOI: 10.2340/ao.v65.45118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Oncologica, 2026. Verfasst von Stefanía Ásta Tryggvadóttir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Hauptthemen laut MEDLINE: Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose: Lung cancer is the third most common malignancy in Iceland and remains the leading cause of cancer-related mortality. Lung cancer may harbor driver mutations affecting the function of Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), B-raf proto-oncogene (BRAF), RET proto-oncogene (RET), MET proto-oncogene (MET), and NTRK, which can influence the selection of targeted therapies and treatment outcomes. In Iceland, EGFR testing was initiated in 2005, and in 2016, multigene targeted panel became standard for tumor testing. The objective was to determine the uptake of testing and frequency of targeted mutations in lung cancer nationwide, the utilization of targeted therapies, and duration of such treatments.Patients/material and methods: Data on lung cancer diagnoses and stage at diagnosis were obtained from the Icelandic Cancer Registry, and molecular testing results were retrieved from the Department of Pathology at Landspitali University Hospital. Treatment data and outcomes were obtained from a central prescription/death registry and chart reviews.

Results

From 2010 to 2023, 2,528 patients were diagnosed with lung cancer, and 25% underwent ­molecular tumor testing, with 90% of stage IV adenocarcinomas tested in 2023. During comprehensive molecular testing in 2016–2023, targeted mutations were detected in 19.3% of tested patients: EGFR 9.9%, BRAF 2.3%, MET 2.7%, HER2 1.2%, ALK 2.7%, ROS1 0.6%, and RET 0.2%. Among patients found to have targeted mutations (2010–2023), 61.2% received targeted therapy; 33.8% remained on therapy for ≥ 12 months, and 13.5% for ≥ 24 months.

Interpretation

The use of molecular testing has increased significantly in the last 20 years, and the ­adaptation of new targeted therapies has been rapid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMolecular Targeted TherapyHumansProto-Oncogene MasIcelandMutationMaleFemaleErbB ReceptorsAgedRegistriesMiddle AgedProtein-Tyrosine Kinases

Substanzen

Proto-Oncogene MasMAS1 protein, humanErbB ReceptorsProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Icelandic Cancer Registry, Reykjavik, Iceland.
  • Department of Oncology, Landspitali - The National University Hospital of Iceland.
  • Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Oncology, Landspitali - The National University Hospital of Iceland.
  • Department of Oncology, Landspitali - The National University Hospital of Iceland; Molecular Pathology Unit; Department of Pathology.
  • Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Molecular Pathology Unit; Department of Pathology; University of Iceland; BioMedical Center (BMC).

ORCID-Profile: Bylgja Hilmarsdóttir, Sigurdis Haraldsdottir

Zitieren

APA

Tryggvadóttir, S. Á., Stefánsson, G. V., Birgisson, H., Gunnarsson, Ö., Guðbjartsson, T., Harðardóttir, H., Hilmarsdóttir, B., Barkardóttir, R. B., & Haraldsdottir, S. (2026). Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncologica. https://doi.org/10.2340/ao.v65.45118

Vancouver

Tryggvadóttir SÁ, Stefánsson GV, Birgisson H, Gunnarsson Ö, Guðbjartsson T, Harðardóttir H, et al. Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncologica. 2026. doi:10.2340/ao.v65.45118

BibTeX
@article{Tryggvadttir2026,
  author = {Tryggvadóttir, Stefanía Ásta and Stefánsson, Guðlaugur V and Birgisson, Helgi and Gunnarsson, Örvar and Guðbjartsson, Tómas and Harðardóttir, Hrönn and Hilmarsdóttir, Bylgja and Barkardóttir, Rósa B and Haraldsdottir, Sigurdis},
  title = {Targeted therapy in the treatment of lung cancer in Iceland 2010–2023},
  journal = {Acta Oncologica},
  year = {2026},
  doi = {10.2340/ao.v65.45118}
}
Kostenlos starten →